Gabriele Niedermann
YOU?
Author Swipe
View article: Supplementary Figure S2 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S2 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Potency of platinum derivatives to facilitate the RT-induced abscopal effect in the C51 colon carcinoma model.
View article: Supplementary Figure S6 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S6 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Cross-presenting DCs and proliferating CD8+ T cells in tumors and tumor-draining lymph nodes in mice treated with cisplatin-containing triple therapy with and without GSK-872.
View article: Supplementary Table S4 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Table S4 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
ICB trials analyzed in Figure 6C and D.
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Supplementary Figure S1 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S1 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Potency of platinum derivatives to facilitate the RT-induced abscopal effect in the B16-CD133 melanoma model.
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
Purpose:Low-dose radiation therapy (LDRT) may enhance the synergistic anti-tumor effect of combined immunotherapy and stereotactic body radiation therapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluat…
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1<sup>+</sup> Non-Small-Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Author Correction: Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice
Author Correction: Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice Open
View article: Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities Open
Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of no…
View article: Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma
Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma Open
Objectives Survivors after pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are with lifetime risk for second primary malignancy (SPM). This necessitates a thorough analysis to better understand the potential long-term health…
View article: Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models
Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models Open
Background: Hypofractionated radiotherapy (hRT) can induce a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade (ICB). However, clinically, this effect is still…
View article: Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside Open
Management of prostate cancer (PC) might be improved by combining external beam radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with lutetium-177 (177Lu)-labeled PSMA inhibito…
View article: Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials
Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials Open
View article: A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment Open
We prospectively evaluated the effects of stereotactic body radiotherapy (SBRT) on circulating immune cells. Patients with oligo-metastatic and oligo-progressive pulmonary lesions were treated with SBRT with (cSBRT) or without (SBRT group)…
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
Purpose:Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the …
View article: Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
Purpose:Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the …
View article: Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients Open
2 figures,3 tables and 3 texts
View article: IL-2/αIL-2 Complexes Massively Expand Systemic Tumor-Specific T Cells and Enhance Abscopal Responses to Radiation and αPD-1
IL-2/αIL-2 Complexes Massively Expand Systemic Tumor-Specific T Cells and Enhance Abscopal Responses to Radiation and αPD-1 Open
View article: Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice
Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice Open
View article: Supplementary Figure S3 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S3 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
RIPK3 expression in tumor cells in vitro and ex vivo and dependence of extracellular ATP on RIPK1.
View article: Supplementary Figure S7 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S7 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Expression and functional analyses of tumor cells cultured in vitro or analyzed ex vivo.
View article: Supplementary Figure S3 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S3 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
RIPK3 expression in tumor cells in vitro and ex vivo and dependence of extracellular ATP on RIPK1.
View article: Data from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Data from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Purpose:Cisplatin is increasingly used in chemoimmunotherapy and may enhance the T cell–dependent radiation-induced abscopal effect, but how it promotes antitumor immunity is poorly understood. We investigated whether and why cisplatin is …
View article: Supplementary Figure S5 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S5 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Cisplatin induced ferroptosis without affecting ATP release, but not pyroptosis.
View article: Supplementary Figure S11 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S11 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Carboplatin induced Ifnb1, Cxcl10, as well as cytosolic mtDNA and gDNA in C51 cells in vitro.
View article: Supplementary Figure S7 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S7 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Expression and functional analyses of tumor cells cultured in vitro or analyzed ex vivo.
View article: Supplementary Figure S11 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Figure S11 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
Carboplatin induced Ifnb1, Cxcl10, as well as cytosolic mtDNA and gDNA in C51 cells in vitro.
View article: Supplementary Table S1 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Supplementary Table S1 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Open
IC50 of platinum derivatives for B16-CD133 and C51 tumor cells.